Publications by authors named "W L A M de Kort"

Introduction: Patient derived organoids (PDOs) are 3D in vitro models and have shown to better reflect patient and tumor heterogeneity than conventional 2D cell lines. To utilize PDOs in clinical settings and trials for biomarker discovery or drug response evaluation, it is valuable to determine the best way to optimize sample selection for maximum PDO establishment. In this study, we assess patient, tumor and tissue sampling factors and correlate them with successful PDO establishment in a well-documented cohort of patients with head and neck squamous cell carcinoma (HNSCC).

View Article and Find Full Text PDF

Aims: Oral squamous cell carcinoma (OSCC) frequently invades the jaw. The exact mechanism of bone invasion remains unclear. This study investigates (premature) osteoclasts and the expression of its differentiation regulating proteins RANKL, OPG and RANK in patients with OSCC.

View Article and Find Full Text PDF

Background: Survival rates of head and neck squamous cell carcinoma (HNSCC) have only marginally improved in the last decades. Hence there is a need for predictive biomarkers for long-time survival that can help to guide treatment decisions and might lead to the development of new therapies. The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway is the most frequently altered pathway in HNSCC, genes are often mutated, amplificated and overexpressed causing aberrant signaling affecting cell growth and differentiation.

View Article and Find Full Text PDF

Background: Organoids are in vitro three-dimensional structures that can be grown from patient tissue. Head and neck cancer (HNC) is a collective term used for multiple tumor types including squamous cell carcinomas and salivary gland adenocarcinomas.

Methods: Organoids were established from HNC patient tumor tissue and characterized using immunohistochemistry and DNA sequencing.

View Article and Find Full Text PDF
Article Synopsis
  • Adalimumab is often used with methotrexate (MTX) for better treatment of rheumatoid arthritis and this study aimed to explore its effectiveness for chronic plaque psoriasis.
  • The trial compared two groups: one receiving adalimumab alone and the other receiving adalimumab with MTX, analyzing factors like drug survival, response rates, and levels of antidrug antibodies.
  • Results showed that the combination therapy led to fewer antidrug antibodies and a trend towards improved treatment response and drug survival, with no significant safety issues reported.
View Article and Find Full Text PDF